Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS

Animals Humans Mice Adenocarcinoma / genetics Adenocarcinoma of Lung / genetics Cancer-Associated Fibroblasts Lung Neoplasms / genetics Proto-Oncogene Proteins p21(ras) / genetics Tumor Microenvironment / genetics

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
20 09 2023
Historique:
received: 21 02 2023
accepted: 11 09 2023
medline: 22 9 2023
pubmed: 21 9 2023
entrez: 20 9 2023
Statut: epublish

Résumé

The impact of genetic ablation of SOS1 or SOS2 is evaluated in a murine model of KRAS

Identifiants

DOI: 10.1038/s41467-023-41583-1 PMID: 37730692 PMC: PMC10511506
pubmed: 37730692
doi: 10.1038/s41467-023-41583-1
pii: 10.1038/s41467-023-41583-1
pmc: PMC10511506
doi:

Substances chimiques

KRAS protein, human 0
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2
Hras protein, mouse EC 3.6.5.2
Sos1 protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5856

Informations de copyright

© 2023. Springer Nature Limited.

Références

J Med Chem. 2022 Mar 10;65(5):3923-3942
pubmed: 35230841
Transl Oncol. 2021 Dec;14(12):101230
pubmed: 34598083
Expert Opin Ther Pat. 2021 Dec;31(12):1189-1204
pubmed: 34253125
Sci Signal. 2018 Sep 04;11(546):
pubmed: 30181243
Mol Cancer Res. 2015 Sep;13(9):1325-35
pubmed: 26037647
Mol Ther Oncolytics. 2021 Nov 20;23:560-570
pubmed: 34938856
EMBO J. 2000 Feb 15;19(4):642-54
pubmed: 10675333
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
J Med Chem. 2020 Aug 13;63(15):8325-8337
pubmed: 32673492
Expert Opin Pharmacother. 2021 Dec;22(18):2475-2482
pubmed: 34281457
J Med Chem. 2022 Feb 24;65(4):3123-3133
pubmed: 34889605
ACS Med Chem Lett. 2023 Jan 12;14(2):183-190
pubmed: 36793426
Mol Cell Biol. 2018 Jul 30;38(16):
pubmed: 29844066
Adv Cancer Res. 2022;153:169-203
pubmed: 35101230
Nature. 2008 Apr 3;452(7187):646-9
pubmed: 18344980
Cancer Discov. 2022 Apr 1;12(4):924-937
pubmed: 35046095
Mol Cell Biol. 2013 Nov;33(22):4562-78
pubmed: 24043312
Nat Genet. 2001 Sep;29(1):25-33
pubmed: 11528387
J Leukoc Biol. 2019 Oct;106(4):815-822
pubmed: 30720883
Nature. 2001 Apr 26;410(6832):1111-6
pubmed: 11323676
Oncogene. 2016 Dec 15;35(50):6389-6402
pubmed: 27157612
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33045063
Small GTPases. 2021 Jan;12(1):67-78
pubmed: 31062644
Oncogene. 2021 Jul;40(27):4538-4551
pubmed: 34120142
Leukemia. 2018 Mar;32(3):820-827
pubmed: 28819285
J Med Chem. 2021 May 27;64(10):6566-6568
pubmed: 33961431
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2551-2560
pubmed: 30683722
Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12407-12
pubmed: 21746917
Cancer Res. 2020 Oct 15;80(20):4414-4425
pubmed: 32699134
Cancers (Basel). 2022 Aug 11;14(16):
pubmed: 36010887
Curr Issues Mol Biol. 2023 Mar 17;45(3):2505-2520
pubmed: 36975534
Int J Mol Sci. 2021 Jun 21;22(12):
pubmed: 34205562
Front Oncol. 2022 Jan 13;11:793121
pubmed: 35096591
Genes (Basel). 2021 Apr 28;12(5):
pubmed: 33924994
Elife. 2020 Sep 08;9:
pubmed: 32897190
BMC Genomics. 2013 Oct 25;14:731
pubmed: 24156637
Angew Chem Int Ed Engl. 2012 Jun 18;51(25):6140-3
pubmed: 22566140
Curr Opin Chem Biol. 2021 Jun;62:109-118
pubmed: 33848766
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Blood. 2018 Dec 13;132(24):2575-2579
pubmed: 30377195
N Engl J Med. 2021 Jun 24;384(25):2447-2449
pubmed: 34161711
Mol Cell Biol. 2000 Sep;20(17):6410-3
pubmed: 10938118
J Mol Endocrinol. 2022 Dec 07;70(1):
pubmed: 36103132
Nat Rev Clin Oncol. 2022 Oct;19(10):637-655
pubmed: 36028717
Biochem Biophys Res Commun. 2022 Dec 31;637:161-169
pubmed: 36403479
Cancer Discov. 2021 Jan;11(1):142-157
pubmed: 32816843
N Engl J Med. 2021 Jun 24;384(25):2382-2393
pubmed: 34161704
Cell Rep. 2022 May 3;39(5):110761
pubmed: 35508122
Nat Commun. 2012;3:1168
pubmed: 23132018
NPJ Precis Oncol. 2021 Nov 29;5(1):98
pubmed: 34845311
Cancers (Basel). 2021 Apr 29;13(9):
pubmed: 33946974
Cell. 2017 Jul 27;170(3):564-576.e16
pubmed: 28753430
Cell. 2018 Feb 8;172(4):857-868.e15
pubmed: 29336889
Immunity. 2017 Dec 19;47(6):1083-1099.e6
pubmed: 29246442
J Med Chem. 2022 Dec 22;65(24):16432-16450
pubmed: 36459180
J Immunol. 2015 Nov 15;195(10):4900-12
pubmed: 26447228
Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4574-9
pubmed: 23487764
Expert Opin Drug Discov. 2022 Mar;17(3):247-257
pubmed: 35084268
Clin Cancer Res. 2022 Apr 14;28(8):1482-1486
pubmed: 34903582
Nat Rev Clin Oncol. 2022 Jun;19(6):402-421
pubmed: 35354979
Mol Carcinog. 2022 Aug;61(8):764-775
pubmed: 35638711
Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188445
pubmed: 33035641
Cancer Res. 2018 Nov 1;78(21):6320-6328
pubmed: 30232219
Leukemia. 2016 Jul;30(7):1542-51
pubmed: 27055865
Cancer Discov. 2021 Aug;11(8):1913-1922
pubmed: 33824136
Nat Med. 2018 Jul;24(7):968-977
pubmed: 29808010

Auteurs

Fernando C Baltanás (FC)

Lab 1. Cancer Research Center, Institute of Cancer Molecular and Cellular Biology, CSIC-University of Salamanca and CIBERONC, 37007, Salamanca, Spain. fcalvo@us.es.
Institute of Biomedicine of Seville (IBiS)/"Virgen del Rocío" University Hospital/CSIC/University of Seville and Department of Medical Physiology and Biophysics, University of Seville, Seville, Spain. fcalvo@us.es.
ORCID: 0000-0001-8110-0991

Rósula García-Navas (R)

Lab 1. Cancer Research Center, Institute of Cancer Molecular and Cellular Biology, CSIC-University of Salamanca and CIBERONC, 37007, Salamanca, Spain.

Pablo Rodríguez-Ramos (P)

Lab 1. Cancer Research Center, Institute of Cancer Molecular and Cellular Biology, CSIC-University of Salamanca and CIBERONC, 37007, Salamanca, Spain.
ORCID: 0000-0002-3766-1406

Nuria Calzada (N)

Lab 1. Cancer Research Center, Institute of Cancer Molecular and Cellular Biology, CSIC-University of Salamanca and CIBERONC, 37007, Salamanca, Spain.

Cristina Cuesta (C)

Lab 5. Cancer Research Center, Institute of Cancer Molecular and Cellular Biology, CSIC-University of Salamanca, 37007, Salamanca, Spain.

Javier Borrajo (J)

Departament of Biomedical Sciences and Diagnostic, University of Salamanca, 37007, Salamanca, Spain.

Rocío Fuentes-Mateos (R)

Lab 1. Cancer Research Center, Institute of Cancer Molecular and Cellular Biology, CSIC-University of Salamanca and CIBERONC, 37007, Salamanca, Spain.
ORCID: 0000-0002-6933-6958

Andrea Olarte-San Juan (A)

Lab 1. Cancer Research Center, Institute of Cancer Molecular and Cellular Biology, CSIC-University of Salamanca and CIBERONC, 37007, Salamanca, Spain.

Nerea Vidaña (N)

Lab 1. Cancer Research Center, Institute of Cancer Molecular and Cellular Biology, CSIC-University of Salamanca and CIBERONC, 37007, Salamanca, Spain.
ORCID: 0000-0001-9404-2356

Esther Castellano (E)

Lab 5. Cancer Research Center, Institute of Cancer Molecular and Cellular Biology, CSIC-University of Salamanca, 37007, Salamanca, Spain.
ORCID: 0000-0002-8449-4081

Eugenio Santos (E)

Lab 1. Cancer Research Center, Institute of Cancer Molecular and Cellular Biology, CSIC-University of Salamanca and CIBERONC, 37007, Salamanca, Spain. esantos@usal.es.
ORCID: 0000-0003-3565-0321

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Critical requirement of SOS1 for tumor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Critical requirement of SOS1 for tumor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Critical requirement of SOS1 for tumor...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Critical requirement of SOS1 for tumor...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs du thorax › Adénocarcinome pulmonaire › Critical requirement of SOS1 for tumor...
questionsmedicales.fr › Cellules › Cellules du tissu conjonctif › Fibroblastes › Fibroblastes associés au cancer › Critical requirement of SOS1 for tumor...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Critical requirement of SOS1 for tumor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes p21(ras) › Critical requirement of SOS1 for tumor...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Critical requirement of SOS1 for tumor...